Advancing Therapies for Genetic Disorders

Wider Reach, Stronger Studies

Our extensive network of engaged patients assures you of access to hard-to-reach populations affected by genetic disorders. We strategically recruit the most eligible participants and increase study retention by taking biospecimen and data collection directly to the patient’s home. As a fully integrated services solution, you can expect streamlined logistics that allow you to focus on advancing the next therapy instead.

  • Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
  • Cystic Fibrosis (CF)
  • Down Syndrome (Trisomy 21)
  • Duchenne Muscular Dystrophy (DMD)
  • Glucose-6-phosphate-dehydrogenase (G6PD)
  • Hereditary Hemorrhagic Telangiectasia (HHT)
  • Hunter’s Syndrome (MPS II)
  •  Huntington's Disease (HD)
  • Myotonic Dystrophy
  • Spinal Muscular Atrophy

Sanguine's Expertise in Genetic & Rare Diseases


Patient Members


Studies Completed


Contact us to discuss your research needs

Sanguine Services

Patient Biospecimens & Data Collection

Longitudinal & Event-Based Collection

Patient Surveys & Questionnaires

Onsite & Same-Day Healthy Control Programs

Growing insight into the molecular origins of genetic disorders has allowed biomedical science to stand on the cusp of many new treatments finally reaching patients in need. To augment therapeutic development, we ensure you’re working with a sufficient sample size and have a comprehensive view of people living with a genetic disorder. As a partner that is also attuned to the unique study design and privacy requirements necessitated in this field, we enable new opportunities for you to improve patients’ wellbeing faster.

Hepatitis B - Thumbnail

Care About Rare: A Patient-Led Approach to Rare Disease Research


Hybrid by Design: Patient Centricity in Clinical Trials
Duchenne Muscular Dystrophy

Hear From Our Community


“All I can hope is that the work we’re doing, the donations that my children are making, that somehow, future generations will never have to know what Huntington’s disease is.”

- Frances Saldana

President of UCI Huntington’s Disease, Care, Patient Advocate

Featured Publications

Molecular Therapy - Nucleic Acids

Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification


Subscribe to our Newsletter

Select what you would like to receive directly in your email